| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,352 | 0,362 | 16:40 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | BOAN BIOTECH: Phase 3 Clinical Trial in China of Tumor Immunotherapy Drug Meets Primary Endpoint | 1 | AASTOCKS | ||
| Di | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT COMPLETION OF PHASE 3 TRIAL OF BA1104 (NIVOLUMAB) IN CHINA, WITH PRIMARY ENDPOINT MET | 2 | HKEx | ||
| SHANDONG BOAN BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 06.11. | BOAN BIOTECH BA2201 Approved for Clinical Trial in China | 1 | AASTOCKS | ||
| 06.11. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT CDE APPROVAL OF IND APPLICATION IN CHINA FOR BA2201, A TL1A/IL-23 BISPECIFIC ANTIBODY FOR THE TREATMENT OF ... | 2 | HKEx | ||
| 30.10. | BOAN BIOTECH Reaches Licensing Partnership for Denosumab Injection in Japan | 1 | AASTOCKS | ||
| 30.10. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT THE COMPANY ENTERS INTO LICENSING AGREEMENT FOR DENOSUMAB INJECTION 60 MG IN JAPAN | 1 | HKEx | ||
| 23.10. | BOAN BIOTECH BA1203 China Phase I Clinical Trial Completes First Patient Dosing | 4 | AASTOCKS | ||
| 22.10. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN PHASE I CLINICAL TRIAL OF BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN) IN CHINA | - | HKEx | ||
| 09.10. | BOAN BIOTECH (06955): CONTINUING CONNECTED TRANSACTIONS PROMOTION COOPERATION AGREEMENT | 1 | HKEx | ||
| 29.09. | BOAN BIOTECH (06955): INTERIM REPORT 2026 | - | HKEx | ||
| 17.09. | BOAN BIOTECH (06955): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 14.09. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT CDE APPROVAL OF IND APPLICATION FOR BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN) | - | HKEx | ||
| 09.09. | BOAN BIOTECH (06955): SUPPLEMENTAL AGREEMENT IN RELATION TO DISCLOSEABLE TRANSACTION FINANCE LEASE AGREEMENT | 2 | HKEx | ||
| 04.09. | BOAN BIOTECH (06955): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 28.08. | BOAN BIOTECH (06955): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 27.08. | BOAN BIOTECH (06955): DISCLOSEABLE TRANSACTION FINANCE LEASE AGREEMENT | 1 | HKEx | ||
| 27.08. | BOAN BIOTECH (06955): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026 | 1 | HKEx | ||
| 26.08. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT CDE ACCEPTANCE OF IND APPLICATION FOR TL1A/IL-23 BISPECIFIC ANTIBODY BA2201 | - | HKEx | ||
| 14.08. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT COMPLETION OF PHASE IA CLINICAL TRIAL OF BA1302 (CD228-DIRECTED ADC) IN CHINA | 1 | HKEx | ||
| 14.08. | BOAN BIOTECH (06955): NOTICE OF BOARD MEETING | 1 | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| CG ONCOLOGY | 82,85 | +3,56 % | Guggenheim raises CG Oncology stock price target on trial results | ||
| SUMMIT THERAPEUTICS | 10,650 | +1,43 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| PRAXIS PRECISION MEDICINES | 318,84 | +4,52 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| RECURSION PHARMACEUTICALS | 2,875 | +5,70 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| KYMERA THERAPEUTICS | 120,30 | -1,00 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,850 | +4,00 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| BIONTECH | 75,35 | -1,63 % | BioNTech-Aktie: Totes Kapital? | Die Aktie von BioNTech bleibt trotz des rückläufigen Impfstoffgeschäfts ein spannender Titel am Aktienmarkt. Anleger richten ihren Blick zunehmend auf die milliardenschwere Forschungspipeline im Bereich... ► Artikel lesen | |
| EVOTEC | 2,728 | 0,00 % | Evotec-Aktie: Gewinn- und Umsatzrekord? | Die Aktie des Hamburger Wirkstoffforschers Evotec bleibt ein spannender, aber risikoreicher Titel am deutschen Aktienmarkt. Nach schwierigen Monaten sorgen erste operative Fortschritte, neue Partnerschaften... ► Artikel lesen | |
| ERASCA | 14,140 | +2,61 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| MODERNA | 176,48 | -1,56 % | Moderna, Bayer, Merck investieren Milliarden - doch bei Psychedelika fehlt ein entscheidendes Teil | ||
| DYNE THERAPEUTICS | 16,520 | +3,12 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| COGENT BIOSCIENCES | 28,390 | +1,94 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| VOR BIOPHARMA | 18,150 | +1,79 % | Vor Biopharma auf der Jefferies Global Healthcare Conference: Finanzstarker Vorstoß bei Autoimmunerkrankungen | ||
| ABSCI | 8,350 | +2,02 % | Absci auf der Jefferies Global Healthcare Conference: Milliardenmarkt für neuartigen Haarausfall-Wirkstoff im Fokus |